Overexpression of YKL-40 is an independent prognostic marker in gastric cancer

Human Pathology

Volumn 40, Issue 12, 2009, Pages 1790-1797

  Bi, Jiong ^a   Lau, Sze Hang ^b   Lv, Zi Li ^c   Xie, Dan ^d   Li, Wen ^a   Lai, Ying Rong ^a   Zhong, Jue Min ^a   Wu, Hui qun ^a   Su, Qiao ^a   He, Yu long ^a   Zhan, Wen Hua ^a   Wen, Jian Ming ^a   Guan, Xin Yuan ^b,d  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGXI MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Gastric carcinoma; Prognostic marker; Tissue microarray; YKL 40

Indexed keywords

GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TRANSPORT; STOMACH CANCER; STOMACH MUCOSA; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LECTINS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 70449094665     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.07.005     Document Type: Article

References (41)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Alberts S.R., Cervantes A., and van de Velde C.J. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14 Suppl 2 (2003) 31-36
3. Tsugane S., and Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 10 (2007) 75-83
4. Jemal A., Tiwari R.C., Murray T., et al. Cancer Statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
5. Recklies A.D., White C., and Ling H. The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365 (2002) 119-126
6. De Ceuninck F., Gaufillier S., Bonnaud A., et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 285 (2001) 926-931
7. Malinda K.M., Ponce L., Kleinman H.K., Shackelton L.M., and Millis A.J. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250 (1999) 168-173
8. Cintin C., Johansen J.S., Christensen I.J., et al. Serum YKL-40 and colorectal cancer. Br J Cancer 79 (1999) 1494-1499
9. Tanwar M.K., Gilbert M.R., and Holland E.C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62 (2002) 4364-4368
10. Johansen J.S., Drivsholm L., Price P.A., and Christensen I.J. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 46 (2004) 333-340
11. Johansen J.S., Bojesen S.E., Mylin A.K., et al. Elevated Plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 27 (2009) 572-578
12. Bergmann O.J., Johansen J.S., Klausen T.W., et al. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res 11 (2005) 8644-8652
13. Johansen J.S., Cintin C., Jørgensen M., Kamby C., and Price P.A. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 31A (1995) 1437-1442
14. Brasso K., Christensen I.J., Johansen J.S., et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66 (2006) 503-513
15. Schmidt H., Johansen J.S., Gehl J., et al. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106 (2006) 1130-1139
16. Pelloski C.E., Mahajan A., Maor M., et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11 (2005) 3326-3334
17. Nutt C.L., Betensky R.A., Brower M.A., et al. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11 (2005) 2258-2264
18. Kim S.H., Das K., Noreen S., Coffman F., and Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol 5 (2007) 17
19. Lau S.H., Sham J.S., Xie D., et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25 (2006) 1242-1250
20. World Health Organization (WHO). Tumours of the stomach. In: Hamilton S.R., and Aaltonen L.A. (Eds). World Health Organization classification of tumours. Tumours of the digestive system (2000), IARC Press, Lyon 37-68
21. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd Eng ed. Gastric Cancer 1 (1998) 10-24
22. UICC. In: Sobin L.H., and Wittekind C. (Eds). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York
23. Xie D., Sham J.S., Zeng W.F., et al. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107 (2003) 896-902
24. Johansen J.S., Williamson M.K., Rice J.S., and Price P.A. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7 (1992) 501-511
25. Roslind A., Balslev E., Kruse H., Staergaard B., and Horn T. Subcellular localization of YKL-40 in normal and malignant epithelial cells of the breast. Ultrastruct Pathol 32 (2008) 101-106
26. Roslind A., Johansen J.S., Christensen I.J., et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer 122 (2008) 857-863
27. Baeten D., Boots A.M., Steenbakkers P.G., et al. Human cartilage gp-391,CD161 monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 43 (2000) 233-243
28. Volck B., Johansen J.S., Stoltenberg M., et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the join pathology. Osteoarthritis Cartilage 9 (2001) 203-214
29. Johansen J.S., Christoffersen P., Møller S., et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 32 (2000) 911-920
30. Huang Y., Prasad M., Lemon W.J., et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98 (2001) 15044-15049
31. Sjogren H., Meis-Kindblom J.M., Orndal C., et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol 162 (2003) 781-792
32. Jensen B.V., Johansen J.S., and Price P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 9 (2003) 4423-4434
33. Ling H., and Recklies A.D. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-a. Biochem J 380 (2004) 651-659
34. + glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol (2009) 10.1007/s11060-009-9919-z Electronic publication ahead of print
35. Nigro J.M., Misra A., Zhang L., et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65 (2005) 1678-1686
36. Junker N., Johansen J.S., Hansen L.T., Lund E.L., Kristjansen P.E., and Kristjansen P.E.G. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 96 (2005) 183-190
37. Saidi A., Javerzat S., Bellahcène A., et al. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 122 (2008) 2187-2198
38. Gronlund B., Høgdall E.V., Christensen I.J., et al. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125). Int J Biol Markers 21 (2006) 141-148
39. Pelloski C.E., Lin E., Zhang L., and Yung W.K. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 12 (2006) 3935-3941
40. Qiao M., Sheng S., and Pardee A.B. Metastasis and AKT activation. Cell Cycle. 7 (2008) 2991-2996
41. Roukos D.H., Murray S., and Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of Cancer. Cancer Bio Ther 6 (2007) 308-312